GT199900171A - Concentrado oral de sertralina. - Google Patents
Concentrado oral de sertralina.Info
- Publication number
- GT199900171A GT199900171A GT199900171A GT199900171A GT199900171A GT 199900171 A GT199900171 A GT 199900171A GT 199900171 A GT199900171 A GT 199900171A GT 199900171 A GT199900171 A GT 199900171A GT 199900171 A GT199900171 A GT 199900171A
- Authority
- GT
- Guatemala
- Prior art keywords
- provides
- concentrate
- concentrated
- composition
- sertraline
- Prior art date
Links
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract 2
- 229960002073 sertraline Drugs 0.000 title abstract 2
- 239000012141 concentrate Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA UNA COMPOSICION FARMACEUTICA CONCENTRADA, LIQUIDA, ESENCIALMENTE NO ACUOSA, PARA LA ADMINISTRACION ORAL, QUE CONTIENE SERTRALINA (FORMULA ESTRUCTURALI) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y UNO O MAS EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. LA PRESENTE INVENCION TAMBIEN PROPORCIONA UN USO DE ESTA COMPOSICION CONCENTRADA PARA PREPARAR UNA SOLUCION ACUOSA DE SERTRALINA. ADEMAS, LA PRESENTE INVENCION PROPORCIONA UN PROCEDIMIENTO DE USO DE ESTA COMPOSICION CONCENTRADA PARA TRATAR O PREVENIR UNA DIVERSIDAD DE ENFERMEDADES O AFECCIONES. FINALMENTE, LA PRESENTE INVENCION PROPORCIONA EL COMPUESTO METANOSULFONATO DE (1SCIS)4(3,4DICLOROFENIL)1,2,3,4 TETRAHIDRONMETIL1NAFTALENOAMINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10402498P | 1998-10-13 | 1998-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT199900171A true GT199900171A (es) | 2001-03-28 |
Family
ID=22298286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT199900171A GT199900171A (es) | 1998-10-13 | 1999-10-05 | Concentrado oral de sertralina. |
Country Status (45)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ299712B6 (cs) | 1999-09-03 | 2008-10-29 | Apbi Holdings, Llc | Použití dapoxetinu pro zvládnutí sexuální dysfunkce podáváním zpusobem podle potreby |
| US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| EP1626950A4 (en) * | 2003-05-23 | 2007-05-23 | Transform Pharmaceuticals Inc | SERTRALINZUSAMMENSETZUNGEN |
| WO2005034910A1 (en) * | 2003-10-08 | 2005-04-21 | Ranbaxy Laboratories Limited | Oral liquid pharmaceutical compositions of sertraline |
| WO2007052152A2 (en) * | 2005-11-07 | 2007-05-10 | Aurobindo Pharma Limited | Sertraline oral concentrate |
| US20080268067A1 (en) | 2007-03-09 | 2008-10-30 | Llinas Rodolfo R | Methods and Compositions for Treating Thalamocortical Dysrhythmia |
| CN109908354A (zh) * | 2017-12-12 | 2019-06-21 | 万特制药(海南)有限公司 | 盐酸舍曲林口服浓缩液及其制备工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US5130338A (en) * | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
| ATE96999T1 (de) * | 1989-08-30 | 1993-11-15 | Pfizer | Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen. |
| US4940731A (en) * | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| SE508372C2 (sv) * | 1995-02-13 | 1998-09-28 | Kjell Lindstroem | Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar |
| ES2192217T3 (es) * | 1995-07-17 | 2003-10-01 | Pfizer | Sertralina para el tratamiento de pacientes tras un infarto de miocardio. |
| WO1999001113A1 (en) * | 1997-07-01 | 1999-01-14 | Pfizer Products Inc. | Gelatine encapsulated solution dosage forms of sertraline |
-
1999
- 1999-09-22 BR BR9914418-2A patent/BR9914418A/pt not_active Application Discontinuation
- 1999-09-22 PT PT99943168T patent/PT1121107E/pt unknown
- 1999-09-22 DK DK99943168T patent/DK1121107T3/da active
- 1999-09-22 OA OA1200100087A patent/OA11662A/en unknown
- 1999-09-22 NZ NZ510756A patent/NZ510756A/en unknown
- 1999-09-22 AT AT99943168T patent/ATE254453T1/de not_active IP Right Cessation
- 1999-09-22 EP EP99943168A patent/EP1121107B1/en not_active Expired - Lifetime
- 1999-09-22 YU YU26401A patent/YU26401A/sh unknown
- 1999-09-22 AU AU56436/99A patent/AU766202B2/en not_active Ceased
- 1999-09-22 GE GEAP19995852A patent/GEP20032969B/en unknown
- 1999-09-22 TR TR2001/01090T patent/TR200101090T2/xx unknown
- 1999-09-22 WO PCT/IB1999/001571 patent/WO2000021521A2/en not_active Ceased
- 1999-09-22 CN CNB998120871A patent/CN1184962C/zh not_active Expired - Fee Related
- 1999-09-22 HU HU0104470A patent/HUP0104470A3/hu unknown
- 1999-09-22 HK HK02101974.6A patent/HK1040199B/zh not_active IP Right Cessation
- 1999-09-22 CA CA002346335A patent/CA2346335C/en not_active Expired - Fee Related
- 1999-09-22 JP JP2000575497A patent/JP3792514B2/ja not_active Expired - Fee Related
- 1999-09-22 SK SK458-2001A patent/SK4582001A3/sk unknown
- 1999-09-22 KR KR10-2001-7004559A patent/KR100417200B1/ko not_active Expired - Fee Related
- 1999-09-22 UA UA2001042450A patent/UA72743C2/uk unknown
- 1999-09-22 EA EA200100285A patent/EA003990B1/ru not_active IP Right Cessation
- 1999-09-22 PL PL99348119A patent/PL348119A1/xx not_active Application Discontinuation
- 1999-09-22 ID IDW20010824A patent/ID29845A/id unknown
- 1999-09-22 ES ES99943168T patent/ES2209490T3/es not_active Expired - Lifetime
- 1999-09-22 AP APAP/P/2001/002119A patent/AP2001002119A0/en unknown
- 1999-09-22 DE DE69912978T patent/DE69912978T2/de not_active Expired - Fee Related
- 1999-09-22 EE EEP200100221A patent/EE04868B1/xx not_active IP Right Cessation
- 1999-09-22 HR HR20010263A patent/HRP20010263B1/xx not_active IP Right Cessation
- 1999-09-22 CZ CZ20011286A patent/CZ20011286A3/cs unknown
- 1999-09-28 PA PA19998483301A patent/PA8483301A1/es unknown
- 1999-10-05 GT GT199900171A patent/GT199900171A/es unknown
- 1999-10-06 TW TW088117244A patent/TWI228043B/zh not_active IP Right Cessation
- 1999-10-08 AR ARP990105116A patent/AR014082A1/es unknown
- 1999-10-09 GC GCP1999314 patent/GC0000175A/en active
- 1999-10-11 MY MYPI99004384A patent/MY122477A/en unknown
- 1999-10-11 PE PE1999001025A patent/PE20001108A1/es not_active Application Discontinuation
- 1999-10-12 TN TNTNSN99190A patent/TNSN99190A1/fr unknown
- 1999-10-12 MA MA25814A patent/MA26698A1/fr unknown
- 1999-10-12 EG EG127599A patent/EG23818A/xx active
- 1999-10-12 DZ DZ990213A patent/DZ2913A1/xx active
- 1999-10-13 CO CO99065089A patent/CO5150213A1/es unknown
-
2001
- 2001-03-23 IS IS5906A patent/IS2239B/is unknown
- 2001-04-09 ZA ZA200102900A patent/ZA200102900B/xx unknown
- 2001-04-10 BG BG105434A patent/BG65085B1/bg unknown
- 2001-04-10 NO NO20011829A patent/NO20011829L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| CO5271759A1 (es) | Formulacion en solucion que contiene una mezcla de disolventes | |
| DE69906518D1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
| MX9505182A (es) | Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p. | |
| GT199800150A (es) | Derivados de resorcinol. | |
| RU94041223A (ru) | Средство для лечения мотонейроновых заболеваний | |
| BR0009042A (pt) | Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| BR0012082A (pt) | Formulação farmacêutica para administração compreendendo morfina e seu uso | |
| DK0583421T3 (da) | Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse | |
| GT199900015A (es) | Procedimiento para tratar la insuficiencia cardiaca | |
| BR0012951A (pt) | Agonistas de retinóides seletivos | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| BR0306306A (pt) | Composição contendo extrato de matricária e uso desta | |
| BR0113590A (pt) | 7-oxo-piridopirimidinas | |
| AR035889A1 (es) | Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos | |
| BR9814498A (pt) | Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica | |
| ES2124983T3 (es) | Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno. | |
| HU229598B1 (en) | Preparations for the application of anti-inflammatory agents | |
| BRPI0409413A (pt) | composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável | |
| GT199900171A (es) | Concentrado oral de sertralina. | |
| BR9915729A (pt) | Amidas Èmega de n-arilsulfonil-aminoácido | |
| AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
| ES2157221T3 (es) | Composiciones metaloporfirinicas. | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto |